The conference was dedicated to 15 years of Kazakhstan first “in vitro”child birth and gathered 250 participants from Europe countries and CIS.

This conference has been organized and sponsored by Sona-Pharm LLC. More than 100 delegates from Ukraine, Kazakhstan, Russia and Moldova took part in this conference; leading experts in IVF from the USA, France, Finland, Israel, Ukraine and Russia presented their lectures. Within the plenary session crucial issues concerning organizational management of IVF-clinic on all possible levels, from the culture of patient care and control on medical procedures to the staff management and brand creation were discussed. Conference was held in a splendid place, Intercontinental Hotel, and in the evening participants could enjoy friendly talks, pleasant music and exquisite cuisine at the restaurant “Stare Zaporizziya”.

From 1st of April, 2011 Merck Serono S.A., Switzerland, authorized and gave exclusive rights to Sona-Pharm LLC to represent pharmaceutical products (Gonal-f, Ovitrelle, Cetrotide, Crinone, Luveris) on the territory of Republic of Kazakhstan. Within the agreement Sona-Pharm LLC is authorized to provide full regulatory support for the products above mentioned including registration, renewal, pharmacovigilance, as well as to realize commercial activities, management of distribution, to perform marketing activities according to global marketing plan.

ESHRE CAMPUS SYMPOSIUM and Annual Meeting of the Ukrainian Association of Reproductive Medicine (UARM) will be held on 26-28 May, 2010 in Kiev organized by European Society of Human Reproduction and Embryology (ESHRE) together with Ukrainian Association of Reproductive Medicine and with assistance of the Ministry of Public Health of Ukraine, Ukrainian State Institute of Reproductive Medicine, National Medical Academy of Post-graduate Education named after Shupik and Sona-pharm LLC. The provident specialists from Great Britain, Germany, the Netherlands, Italy, Greece, Belgium and Russia will participate in this symposium. Theoretical and practical options for women with fertility problems will be clarified. Results in additional reproductive technologies will be reported. Sona-pharm is the General Sponsor of this symposium and it will conduct Pergoveris Launch Symposium within its' bounds. For more information, please click http://www.uarm.org.ua

A new drug Pergoveris to treat infertility is registered. Pergoveris is a combination of follitropin alfa (r-hFSH) 150 IU and lutropin alfa (r-hLH) 75 IU. Pergoveris is a highly effective, safe and easy to use drug in ART due to recombinant technology and FSH and LH optimal ratio. For more information, please click http://www.merckserono.com/en/therapeutic_areas/fertility/infertility/pergoveris/pergoveris.html